The researchers behind the new AI system explained IPF is a good candidate for this type of technology, since existing ...

At 12 weeks, patients treated with ENV-101 showed statistically significant increases in lung volume compared with those ...

VANCOUVER, British Columbia, May 11, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Comp ...

Antony says there is a critical need for a better predictive model for IPF. Animal models of the disease are disappointing, and more traditional two dimensional cellular models are insufficient.

One mid-stage study is going to use this LPA1R antagonist drug for the treatment of patients with IPF, and then the other mid-stage study will use this very same drug for the treatment of patients ...

For the first time, two drugs are approved specifically for the treatment of idiopathic pulmonary fibrosis (IPF). In this interview, Steven Nathan, MD, offers guidance on using these new treatments.

--Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company, is pleased to announce that it has begun screening patients for suitability for enrolment in its Phase 2 ...

Inhibiting PDE4B is a promising approach in IPF, the group asserted, based on studies in animal models and human tissues in vitro. Inflammation, in which PDE4 enzymes are heavily involved, is seen ...

Tested on cellular systems and animal models, ... In February 2021, Insilico nominated INS018_055 as a preclinical candidate for the treatment of IPF, ...

--Algernon Pharmaceuticals Inc. a clinical stage pharmaceutical development company is pleased to announce that it has reached 50% of its enrollment target for its Phase 2 idiopathic pulmonary ...